Physician profile
Hewatt M Sims
NPI 1386653061
$376,318.93
in general payments reported to CMS, 2019-2025
30 companies · $54K in 2025
The $54K reported for 2025 was more than what 88% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $55K · 2021: $36K · 2022: $1,360 · 2023: $48K · 2024: $72K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $90K · Consulting Fee: $70K · Travel and Lodging: $12K · Food and Beverage: $2,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $90,151.75 |
| Consulting Fee | $69,750.00 |
| Travel and Lodging | $12,052.56 |
| Food and Beverage | $2,493.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Precision Spine, INC. | $183,673.38 | 2019-2025 | |
| Spineart Sa | $70,268.00 | 2023-2025 | Cure LP - Anterior Lumbar Plate |
| Medical Investment Advisors LLC | $68,276.02 | 2019-2021 | |
| Arteriocyte Medical Systems, INC. | $40,000.00 | 2019 | |
| Zavation Medical Products, LLC | $5,017.29 | 2020 | |
| Cgg Medical INC | $2,441.86 | 2025 | |
| Intelivation Technologies, LLC | $1,750.00 | 2021-2022 | |
| Spineology INC. | $1,604.71 | 2020-2024 | Optimesh Expandable Interbody Fusion System |
| Boston Scientific Corporation | $791.32 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Medical Device Business Services, INC. | $771.74 | 2025 | Velys |
| Spinal Simplicity, LLC | $571.31 | 2022-2024 | Ha Minuteman G3-R, Liberty Si |
| Depuy Synthes Sales INC. | $288.08 | 2021-2025 | Teligen, Fibergraft Bg Morsels, Skyline |
| Choice Spine, LLC | $248.57 | 2025 | Stratofuse, Blackhawk Cervical Spacer System, Veo Lateral Interbody Fusion System |
| Stryker Corporation | $79.72 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $74.97 | 2021-2025 | Exparel |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $73.26 | 2024-2025 | |
| Intrinsic Therapeutics | $52.00 | 2021 | |
| Smith+Nephew, INC. | $48.54 | 2019-2025 | Collagenase Santyl |
| Nalu Medical, INC. | $47.25 | 2022 | |
| Bioventus LLC | $35.71 | 2022-2024 | Bonescalpel & Sonicone (O.R.) |
| Amgen INC. | $27.62 | 2024 | Krystexxa |
| Zimmer Biomet Holdings, INC. | $27.38 | 2022 | |
| Arthrex, INC. | $24.00 | 2025 | |
| Pacira Therapeutics, INC. | $21.64 | 2019 | |
| Si-Bone, INC. | $21.00 | 2019 | |
| Medtronic, INC. | $20.39 | 2025 | Inceptiv |
| Portola Pharmaceuticals, LLC | $19.32 | 2019 | |
| Acacia Pharma INC | $17.56 | 2021 | |
| Wright Medical Technology, INC. | $14.30 | 2019 | |
| Pfizer INC. | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hewatt Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.